Cardoso F et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12(5):615-20. Abstract.

Dittadi R et al. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001;16(4):255-61. Abstract.

Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30(3):259-65. Abstract.

Niehans GA et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85(15):1230-5. Abstract.

Sekido Y et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003;22(6):1225-32. Abstract.

Simon R et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93(15):1141-6. Abstract.

Tanner M et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61(14):5345-8. Abstract.

Tuziak T et al. Expression of HER2/neu in primary and metastatic breast cancer. Pol J Pathol 2001;52(1-2):21-6. Abstract.

Vincent-Salomon A et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94(8):2169-73. Abstract.